Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Eunice Lee Kwak

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108626576. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 0, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2007: 2 trials · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 3 papers · 2013: 3 papers · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper

Papers 15

  1. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  2. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Co-author DOI 10.1001/jamaoncol.2018.0329↗
  3. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000336↗
  4. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  5. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  6. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  7. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Co-author DOI 10.1016/j.prro.2013.07.006↗
  8. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2013.10.027↗
  9. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at… Co-author DOI 10.1002/cncr.28329↗
  10. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Co-author DOI 10.1097/sla.0b013e318263da2f↗
  11. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Co-author DOI 10.1634/theoncologist.2012-0435↗
  12. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Co-author DOI 10.1002/cncr.26633↗
  13. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Last author DOI 10.1007/s10637-011-9708-3↗
  14. A matter of timing: is there a role for radiation in locally advanced pancreatic cancer, and if so, when? Last author DOI 10.14694/edbook_am.2012.32.14↗
  15. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Co-author DOI 10.1016/j.ijrobp.2009.10.061↗

Trials 2

  1. Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer Principal investigator NCT00568646↗
  2. Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer Principal investigator NCT00593008↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 14 shared papers, 2011–2019 · strength 0.61
  2. David P. Ryan · 14 shared papers, 2011–2019 · strength 0.58
  3. Lawrence Scott Blaszkowsky · 14 shared papers, 2011–2019 · strength 0.58
  4. Jennifer Yon-Li Wo · 12 shared papers, 2012–2019 · strength 0.55
  5. Cristina Rosa Ferrone · 10 shared papers, 2013–2019 · strength 0.47
  6. Keith D. Lillemoe · 9 shared papers, 2013–2019 · strength 0.44
  7. Carlos F. Fernandez-del Castillo · 10 shared papers, 2011–2018 · strength 0.43
  8. Jason Edward Faris · 6 shared papers, 2012–2019 · strength 0.29
  9. Janet E. Murphy · 5 shared papers, 2013–2019 · strength 0.26
  10. Ryan David Nipp · 2 shared papers, 2018–2019 · strength 0.13
  11. Carlos Fernández-del Castillo · 3 shared papers, 2013–2019 · strength 0.13
  12. Harvey J. Mamon · 4 shared papers, 2011–2014 · strength 0.13
  13. David Tsai Ting · 2 shared papers, 2015–2019 · strength 0.10
  14. Andrew Louis Warshaw · 3 shared papers, 2013–2015 · strength 0.10
  15. Vikram Deshpande · 3 shared papers, 2013–2015 · strength 0.10
  16. Rakesh K. Jain · 2 shared papers, 2014–2019 · strength 0.09
  17. Yves Boucher · 2 shared papers, 2014–2019 · strength 0.09
  18. Dan Gabriel Duda · 2 shared papers, 2014–2019 · strength 0.09
  19. Florence K. Keane · 1 shared paper, 2018 · strength 0.08
  20. Nilesh P. Talele · 1 shared paper, 2019 · strength 0.06
  21. Motaz Qadan · 1 shared paper, 2019 · strength 0.06
  22. Aparna R. Parikh · 1 shared paper, 2019 · strength 0.06
  23. Ryan Bruce Corcoran · 1 shared paper, 2019 · strength 0.06
  24. Colin D. Weekes · 1 shared paper, 2019 · strength 0.06
  25. Thomas Adam Abrams · 2 shared papers, 2012–2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.